Shares of Cytokinetics CYTK gained 2.2% on Wednesday after the company began enrolling patients in its mid-stage study of CK-4021586 (CK-586), a cardiac myosin inhibitor, for treating heart failure ...

Cytokinetics (NASDAQ:CYTK – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities research analysts at HC ...

Cytokinetics receives a Buy rating from Stifel, with a promising outlook for aficamten in the $3 billion U.S. oHCM market, ...

Edgewise Therapeutics (EWTX) stock traded flat as Stifel launched its coverage with a Hold recommendation, indicating a ...

JMP Securities analyst Jason Butler reiterated a Buy rating on Cytokinetics (CYTK – Research Report) today and set a price target of ...

Morgan Stanley analyst Jeffrey Hung maintained a Hold rating on Cytokinetics (CYTK – Research Report) today and set a price target of ...

Getty Images Holdings has a lower P/E than the aggregate P/E of 66.37 of the Interactive Media & Services industry. Ideally, one might believe that the stock might perform worse than its peers ...

Cytokinetics is on track to complete its New Drug Application ... This timeline is ahead of many investors’ expectations and could serve as a positive catalyst for the stock. Recent interactions with ...

SOUTH SAN FRANCISCO, Calif., Jan. 03, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on December 31, 2024 it granted stock options to purchase an aggregate ...